Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1994 3
1995 5
1996 4
1997 4
1998 7
1999 8
2000 6
2001 10
2002 8
2003 10
2004 4
2005 8
2006 3
2007 9
2008 4
2010 2
2011 2
2012 1
2013 3
2014 4
2015 4
2017 3
2018 3
2019 1
2020 1
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 11535718

118 results

Results by year

Filters applied: . Clear all
Page 1
Experience with indium-111 and yttrium-90-labeled somatostatin analogs.
Virgolini I, Traub T, Novotny C, Leimer M, Füger B, Li SR, Patri P, Pangerl T, Angelberger P, Raderer M, Burggasser G, Andreae F, Kurtaran A, Dudczak R. Virgolini I, et al. Curr Pharm Des. 2002;8(20):1781-807. doi: 10.2174/1381612023393756. Curr Pharm Des. 2002. PMID: 12171531 Review.
New trends in peptide receptor radioligands.
Virgolini I, Traub T, Novotny C, Leimer M, Füger B, Li SR, Patri P, Pangerl T, Angelberger P, Raderer M, Andreae F, Kurtaran A, Dudczak R. Virgolini I, et al. Q J Nucl Med. 2001 Jun;45(2):153-9. Q J Nucl Med. 2001. PMID: 11476164 Review.
111In-DOTA- dPhe1-Tyr3-octreotide, 111In-DOTA-lanreotide and 67Ga citrate scintigraphy for visualisation of extranodal marginal zone B-cell lymphoma of the MALT type: a comparative study.
Li S, Kurtaran A, Li M, Traub-Weidinger T, Kienast O, Schima W, Angelberger P, Virgolini I, Raderer M, Dudczak R. Li S, et al. Eur J Nucl Med Mol Imaging. 2003 Aug;30(8):1087-95. doi: 10.1007/s00259-003-1206-1. Epub 2003 May 24. Eur J Nucl Med Mol Imaging. 2003. PMID: 12768334 Clinical Trial.
Comparative somatostatin receptor scintigraphy using in-111-DOTA-lanreotide and in-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy.
Virgolini I, Patri P, Novotny C, Traub T, Leimer M, Füger B, Li SR, Angelberger P, Raderer M, Wogritsch S, Kurtaran A, Kletter K, Dudczak R. Virgolini I, et al. Ann Oncol. 2001;12 Suppl 2:S41-5. doi: 10.1093/annonc/12.suppl_2.s41. Ann Oncol. 2001. PMID: 11762351 Free article.
DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy.
Smith-Jones PM, Bischof C, Leimer M, Gludovacz D, Angelberger P, Pangerl T, Peck-Radosavljevic M, Hamilton G, Kaserer K, Kofler A, Schlangbauer-Wadl H, Traub T, Virgolini I. Smith-Jones PM, et al. Endocrinology. 1999 Nov;140(11):5136-48. doi: 10.1210/endo.140.11.7126. Endocrinology. 1999. PMID: 10537142
118 results